Published in
Taylor and Francis Group, Leukemia & Lymphoma, 3(61), p. 714-720, 2019
DOI: 10.1080/10428194.2019.1682571
Links
Tools
A matching-adjusted indirect treatment comparison (MAIC) of daratumumab–bortezomib–melphalan–prednisone (D-VMP) versus lenalidomide–dexamethasone continuous (Rd continuous), lenalidomide–dexamethasone 18 months (Rd 18), and melphalan–prednisone–thalidomide (MPT)
Journal article published in 2019 by
Meletios A. Dimopoulos 
,
Michele Cavo ,
Maria-Victoria Mateos ,
Thierry Facon,
Bart Heeg ,
Sophie van Beekhuizen,
Samron B. Gebregergish,
Sandhya Nair,
Marta Pisini,
Annette Lam ,
Mary Slavcev
,
Michele Cavo ,
Maria-Victoria Mateos ,
Thierry Facon,
Bart Heeg ,
Sophie van Beekhuizen,
Samron B. Gebregergish,
Sandhya Nair,
Marta Pisini,
Annette Lam ,
Mary Slavcev
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 